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ABSTRACT
As part of the Polish external quality assurance scheme, clinical laboratories were asked to send ﬁve
consecutive isolates of Staphylococcus aureus and the corresponding susceptibility results to the national
Centre of Quality Control in Microbiology. Of 1376 isolates submitted as S. aureus from 276 medical
centres, 13 (< 1%) had been misidentiﬁed by local laboratories. Of 181 (13.5%) methicillin-resistant
S. aureus (MRSA) isolates, most were identiﬁed correctly (c. 98% of laboratories). Although all MRSA
isolates were fully susceptible to vancomycin, teicoplanin and linezolid, they were usually multiresist-
ant; almost 23% were resistant to seven antimicrobial agents. Most (> 90%) MSSA isolates were
susceptible to the tested antibiotics, except penicillin (21% susceptible) and tetracycline (62.4%
susceptible). In addition to evaluating the proﬁciency of testing by local laboratories, the study yielded
valuable information regarding the susceptibility patterns of S. aureus isolates in Poland.
Keywords Antimicrobial susceptibility, MRSA, Poland, proﬁciency testing, Staphylococcus aureus, surveillance
Original Submission: 24 August 2004; Revised Submission: 15 October 2004; Accepted: 20 December 2004
Clin Microbiol Infect 2005; 11: 379–385
INTRODUCTION
Staphylococcus aureus is one of the most common
human pathogens, responsible for a variety of
infections in all age groups. It is also challenging
to treat because of its resistance to antimicrobial
agents. In addition to universal b-lactamase pro-
duction, S. aureus isolates resistant to methicillin
(MRSA), and thus resistant to all b-lactam antibi-
otics, have spread worldwide and are responsible
for nosocomial and community outbreaks of
infection [1–3]. In addition, MRSA isolates with
either reduced susceptibility or high-level resist-
ance to vancomycin have now been described
[4,5].
Accurate determination of resistance pheno-
type and the underlying mechanisms of resistance
are of crucial importance, not only for therapy,
but also from a public health perspective. In
addition to internal laboratory quality control
procedures, several national and international
external quality control assurance schemes for
antimicrobial susceptibility testing have been
established in order to assess the proﬁciency of
testing in individual laboratories and to compare
laboratories within a country or on an interna-
tional level [6–10]. The Polish external quality
assurance scheme (POLMICRO) was established
in 1994 and, since 1997, has been coordinated by
the Centre of Quality Control in Microbiology
(CQCM). In the present study, participating
laboratories were asked to send S. aureus isolates,
with the corresponding susceptibility results, to
the CQCM. The isolates were re-identiﬁed and
MICs of a broad panel of antibiotics were deter-
mined by the CQCM in order to evaluate the
testing proﬁciency of the local laboratories and to
gather S. aureus susceptibility data from through-
out Poland.
MATERIALS AND METHODS
Study design
Local laboratories
Laboratories (n = 276) participating in the POLMICRO scheme
sent ﬁve consecutive clinical isolates of S. aureus (one
isolate ⁄patient) (n = 1376) during a 3-month period in 1999–
2000 to the CQCM. Data on susceptibility to antimicrobial
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agents (obtained by disk diffusion tests) and additional
information (e.g., hospital or ambulatory care, type of ward,
site of infection) were collected.
Centre of Quality Control in Microbiology
Most (n = 1005; 73.7%) of the S. aureus isolates were from
hospital-acquired infections, including skin and soft tissue
infections (n = 685; 50.2%), deep abscesses (n = 121; 8.9%),
blood (n = 103; 7.6%), and bone and joint infections (n = 90;
6.6%). Isolates were collected from surgical (n = 388), inter-
nal medicine (n = 96), intensive care (n = 53), obstetric and
gynaecology (n = 56), paediatric (n = 38), dermatology
(n = 37), neonatology (n = 32) and other unspeciﬁed wards.
Most community-derived isolates were recovered from skin
and soft tissue infections. The isolates were re-identiﬁed by
standard procedures [11], based on free coagulase produc-
tion and clumping factor (rabbit plasma; Biomed, Warsaw,
Poland) and DNase production (DNase agar; Mast Diagnos-
tics, Bootle, UK).
Susceptibility testing
Methicillin resistance was determined by disk diffusion with a
1-lg oxacillin disk, an oxacillin agar screening test (performed
when discrepancies between local laboratory and CQCM
results were encountered) [12,13] and detection of the mecA
gene by PCR (performed on all MRSA isolates identiﬁed by
oxacillin disk diffusion) [14]. S. aureus ATCC 29213 (methicil-
lin-susceptible, MSSA) and S. aureus ATCC 43300 (methicillin-
resistant) were included as reference strains.
Antimicrobial susceptibility testing was performed by both
disk diffusion and agar dilution methods according to NCCLS
guidelines [12,13]. The following antimicrobial agents were
used for disk diffusion tests by local laboratories: penicillin,
oxacillin, erythromycin, clindamycin, lincomycin, gentamicin,
tetracycline, doxycycline, ciproﬂoxacin, oﬂoxacin, trimetho-
prim–sulphamethoxazole, teicoplanin, vancomycin, rifampi-
cin, chloramphenicol, nitrofurantoin, fusidic acid (Becton
Dickinson, Franklin Lakes, NJ, USA) and mupirocin (Oxoid,
Basingstoke, UK). S. aureus ATCC 25923 (methicillin-suscept-
ible) was used as the control strain for disk diffusion testing.
MICs were determined for 19 antibiotics (MRSA isolates)
and 24 antibiotics (MSSA isolates) by agar dilution on Mueller–
Hinton-II Agar (Becton Dickinson). An inoculum of 104 CFU
was applied to antibiotic-containing plates with a multipoint
inoculator (West Sussex Instruments Ltd, Denley, UK). The
following antimicrobial agents were tested: penicillin (Sigma,
Munich, Germany), cloxacillin (Polfa Tarchomin, Warsaw,
Poland), amoxycillin–clavulanic acid (SmithKline Beecham,
Philadelphia, PA, USA), cefazolin (Fluka, Buchs, Switzerland),
cefuroxime (Sigma), erythromycin (Fluka), clindamycin (Phar-
macia Upjohn, Kalamazoo, MI, USA), gentamicin (Polfa
Tarchomin), tetracycline (Sigma), doxycycline (Sigma), mino-
cycline (Wyeth Ayerst, St Davids, PA, USA), ciproﬂoxacin
(KRKA, Novo Mesto, Slovenia), moxiﬂoxacin (Bayer, Wup-
pertal, Germany), trimethoprim–sulphamethoxazole (Roche,
Basel, Switzerland), trimethoprim (Roche), teicoplanin (Marion
Merrell, Denham, UK), vancomycin (Lilly, Indianapolis, IN,
USA), rifampicin (Lepetit, Lainate, Italy), chloramphenicol
(Sigma), linezolid (Pharmacia Upjohn), quinupristin–dalfopr-
istin (Aventis Pharma, Romainville, France), nitrofurantoin
(Terpol, Sieradz, Poland), fusidic acid (Aldrich, Taufkirchen,
Germany) and mupirocin (SmithKline Beecham). Breakpoints
for fusidic acid, mupirocin, cloxacillin and doxycycline were
those recommended by Comite´ de l’Antibiogramme de la
Societe´ Francaise de Microbiologie guidelines [15].
S. aureus ATCC 29213 (MSSA), Escherichia coli ATCC 35218
(for b-lactam ⁄ b-lactamase inhibitor combinations) and Pseudo-
monas aeruginosa ATCC 27853 (for Mueller–Hinton agar) were
used for quality control of the susceptibility tests [13]. The
inducible MLSB (iMLSB) phenotype was detected by the
double erythromycin–clindamycin disk test.
RESULTS
Quality control data
Of 1376 isolates submitted as S. aureus, 13 (< 1%)
were misidentiﬁed by local laboratories and
comprised various coagulase-negative species,
such as Staphylococcus haemolyticus, Staphylococcus
epidermidis, Staphylococcus capitis, Staphylococcus
xylosus and Staphylococcus hominis. Of those iso-
lates identiﬁed correctly as S. aureus (n = 1363), 27
(2.0%) were misclassiﬁed according to methicillin
susceptibility, in that 25 were reported as MRSA
instead of MSSA (a major error: no mecA gene
detected) and two as MSSA instead of MRSA
(a very major error). All MRSA isolates were
reported correctly as resistant to all b-lactams.
Interpretative errors detected in the testing of
other antimicrobial agents are shown in Table 1.
Inducible MLSB resistance was not detected in
one isolate by three laboratories, and in two
isolates by one laboratory.
Table 1. Interpretative errors ob-
served following susceptibility test-
ing by disk diffusion
Test result ﬁ
reference result
(error type)
No. of laboratories
Erythromycin Tetracycline Ciproﬂoxacin
Trimethoprim–
sulphamethoxazole Clindamycin Gentamicin
S ﬁ R (very major) 0 5 0 0 0 0
R ﬁ S (major) 4 5 4 7 2 2
S ﬁ I (minor) 0 0 0 0 0 0
I ﬁ S (minor) 11 2 6 2 5 4
R ﬁ I (minor) 0 0 0 0 0 0
I ﬁ R (minor) 0 0 0 0 0 0
Total 15 12 10 9 7 6
S, sensitive; R, resistant; I, intermediate.
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In the histograms of zone diameter distribu-
tions for oxacillin (Fig. 1) and other selected
antimicrobial agents (Fig. 2), unimodal distribu-
tion was seen, indicating good separation of
susceptible and resistant populations. The tetra-
cycline resistance rate was extremely high
(> 46%).
Antibiotic susceptibility results
Most (> 90%) MSSA isolates were susceptible to
most antibiotics, with the exception of penicillin
(21% susceptible) and tetracycline (62.4% suscep-
tible) (Table 2). One mecA-negative isolate was
resistant to cloxacillin and could represent the
BORSA (borderline oxacillin-resistant S. aureus)
phenotype. No differences in the susceptibility
data were observed between hospital and com-
munity isolates of MSSA; thus, the data were
combined. MRSA isolates were fully susceptible to
vancomycin, teicoplanin and linezolid, compared
to tetracycline (18% susceptible), gentamicin (25%
susceptible), erythromycin (31% susceptible) and
ciproﬂoxacin (42% susceptible) (Table 3). Accord-
ing to the MIC data, 51.1% were susceptible to
clindamycin, but when the inducible mechanism
was taken into consideration, only 34.3% were
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Fig. 1. Distribution of oxacillin disk zone diameters.
S, susceptible; I, intermediate; R, resistant.
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susceptible. However, susceptibility to erythro-
mycin was not changed, since all isolates with the
iMLSB phenotype fell into the intermediate cate-
gory (data not shown). Almost 23% of the isolates
exhibited resistance to seven different antimicro-
bial agents.
Prevalence of resistance
In total, 181 (13.3%) isolates were identiﬁed
as methicillin-resistant (mecA-positive). Most
(n = 177; 97.6%) were from hospitalised patients,
originating from intensive care (45.3%), surgical
Table 2. Number of methicillin-susceptible Staphylococcus aureus isolates (n = 1182) with the indicated MICs of selected
antimicrobial agents
Antimicrobial agent
MIC (mg ⁄L)
£ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 MIC50 MIC90 S%
Penicillin 5 87 100 54 150 434 288 47 16 1 – – – – 0.5 1 21
Cloxacillin – 4 29 395 646 106 1 – – 1 – – – – 0.25 0.25 99.9
Amoxycillin–
clavulanic acid
– 15 19 179 329 578 61 1 – – – – – – 0.5 0.5 100
Cefazolin – – 14 26 271 747 102 21 – – 1 – – – 0.5 1 99.9
Cefuroxime – – – 4 33 192 788 161 2 – – 1 – – 1 2 99.9
Erythromycin – – 5 64 841 162 4 (1a) 3 (3a) 5 (5a) 5 (4a) 4 (2a) 10(4a) 79 (43a) – 0.25 0.5 90.7
Clindamycin – 34 (3a) 568 (24a) 456 (25a) 96 (10a) 1 – – – 1 26 – – – 0.06 0.25 97.8 (92.5a)
Gentamicin – – 2 32 705 406 4 3 1 – 1 3 25 – 0.25 0.5 97.7
Tetracycline – 3 21 239 403 66 1 3 2 17 68 210 127 22 0.25 64 62.4
Doxycycline 7 38 229 363 93 17 65 199 137 22 8 4 – – 0.12 4 97.1
Minocycline 5 35 531 467 99 5 7 12 14 7 – – – – 0.12 0.25 99.5
Ciproﬂoxacin – 11 2 36 421 628 68 9 3 2 2 – – – 0.5 0.5 98.6
Moxiﬂoxacin 65 313 632 162 6 1 – 2 1 – – – – – 0.06 0.12 99.7
Trimethoprim–
sulphamethoxazole
12 187 329 180 359 77 7 2 9 7 3 10 – – 0.12 0.25 97.5
Trimethoprim – – – 5 29 304 624 165 29 3 6 4 4 9 1 2 98
Teicoplanin – – 7 10 82 564 512 7 – – – – – – 0.5 1 100
Vancomycin – – – 4 12 745 413 8 – – – – – – 0.5 1 100
Rifampicin 1177 3 – – – – – – – 2 – – – – 0.0075 0.015 99.8
Chloramphenicol – – – – – 7 1 37 341 741 17 9 26 2 8 8 95.4
Linezolid – – 9 3 8 33 352 772 5 – – – – – 2 2 99.6
Quinupristin–
dalfopristin
– 4 1 6 276 834 61 – – – – – – – 0.5 0.5 100
Nitrofurantoin – – – – – – 2 9 35 733 400 3 – – 8 16 100
Fusidic acid 5 88 397 616 72 2 – – 1 1 – – – – 0.12 0.12 99.8
Mupirocin 4 11 264 763 109 1 – – – 1 29 – – – 0.12 0.25 97.4
S, susceptible.
aInducible resistance phenotype MLSB.
Table 3. Number of methicillin-resistant Staphylococcus aureus isolates (n = 181) with the indicated MICs of selected
antimicrobial agents
Antimicrobial agent
MIC (mg ⁄L)
£ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 MIC50 MIC90 S%
Erythromycin – – 2 13 37 1 1 (1a) 5 (5a) 10 (8a) 8 (6a) 3 – 101 (9a) – > 64 > 64 31.4
Clindamycin – 3 28 (4a) 51 (19a) 8 (5a) – – – – – – 91 (1a) – – 0.25 > 32 51.1 (34.3a)
Gentamicin – – – 1 16 24 1 – – – – 2 14 122 128 > 128 25
Tetracycline – 1 2 22 3 1 – – 1 5 33 46 23 44 32 128 18
Doxycycline – 6 16 12 – 4 5 43 46 28 17 4 – 6 4 16 70.7
Minocycline 1 2 20 13 8 10 46 35 28 18 – – – – 1 8 89.9
Ciproﬂoxacin – – 3 9 31 18 11 7 9 43 41 9 – – 4 16 42
Moxiﬂoxacin – 17 33 23 5 3 21 58 19 2 – – – – 1 4 58
Trimethoprim–sulphamethoxazole 2 3 27 41 36 17 15 9 7 4 2 12 – – 0.25 4 86.7
Trimethoprim – – – 7 22 39 53 29 1 5 3 – 1 21 1 128 86.7
Teicoplanin – – 2 9 36 58 33 33 9 1 – – – – 0.5 2 100
Vancomycin – – – – 12 54 85 30 – – – – – – 1 2 100
Rifampicin 106 3 – – – – – 1 1 – 1 69 – – 0.015 > 32 61.7
Chloramphenicol – – – – – – 10 38 81 28 11 3 8 2 4 16 87.2
Linezolid – – – – 21 78 69 13 – – – – – – 0.5 1 100
Quinupristin–
dalfopristin
– – 4 8 41 63 48 17 – – – – – – 0.5 1 90.9
Nitrofurantoin – – – – – – – 1 32 103 45 – – – 8 16 100
Fusidic acid 7 36 19 44 12 3 9 27 23 1 – – – – 0.12 4 87.2
Mupirocin 1 14 94 57 6 – – – 1 – 7 – – 1 0.06 0.12 95.7
S, susceptible.
aInducible resistance phenotype MLSB.
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(17%), internal medicine (16.6%), paediatric
(7.9%) and neonatology (6.3%) wards. MRSA
isolation rates were highest from surgical site
infections (21.9%), joint and bone infections
(20.2%) and blood (19.6%) (Table 4). The preval-
ence of MRSA was higher in secondary- and
tertiary-care institutions (15.3%) than in primary
care (11.7%), and varied signiﬁcantly between
regions, being lowest in the eastern part of Poland
(Fig. 3).
DISCUSSION
In an era of growing antibiotic resistance and the
emergence and spread of multiresistant bacteria,
the accurate detection of susceptibility pheno-
types is crucial for patient management and for
infection control practices. The most important
mechanism of resistance in staphylococci is resist-
ance to methicillin, which in clinical terms signi-
ﬁes resistance to all b-lactam antibiotics, and is
often accompanied by resistance to many other
groups of antimicrobial agents. In addition, clonal
spread of MRSA occurs, with several interna-
tional and local clones causing epidemics [2]. The
recent appearance of community-acquired MRSA
has underlined the importance of accurate detec-
tion of this resistance phenotype outside the
hospital [3,16,17], and therefore many external
quality control schemes, including POLMICRO,
incorporate staphylococci in their programmes
[6,7]. When the POLMICRO programme started
in 1994, c. 50% of participating laboratories were
unable to detect methicillin resistance [18]. The
situation has started to improve as a result of
detailed feedback provided by the CQCM, inclu-
ding updated methodology, detailed analysis of
mistakes and problems encountered (http://
www.polmikro.edu.pl), and provision of free
training. In 1998, misidentiﬁcation of resistance
occurred in 30% of laboratories, decreasing to
12.5% in 2000 [19–21]. In the present study, most
(c. 98%) laboratories identiﬁed MRSA correctly,
and in POLMICRO 2002, < 3% of laboratories
failed to identify resistance correctly [22]. Accu-
rate detection of methicillin resistance was
achieved with the 1-lg oxacillin disk diffusion
test, which appears to be a suitable diagnostic
procedure for laboratories with limited resources.
Only a small proportion of laboratories reported
other antibiotic resistance phenotypes incorrectly.
Since the establishment of POLMICRO, identiﬁ-
cation of S. aureus to the species level has not been
problematic, as also reported by other external
quality control schemes such as UKNEQAS and
the CDC ⁄WHO exercise [10]. In the present study
< 1% of isolates were misidentiﬁed.
Although the main purpose of the present
study was to evaluate the ability of Polish
microbiological laboratories to detect resistance
phenotypes in clinical isolates of S. aureus,
important additional information was also
obtained regarding the incidence of MRSA
throughout the country, and the prevalence of
MRSA with regard to the site of infection and
type of hospital ward affected. Although overall
resistance among hospital isolates was 17.6%, it
was interesting to observe differences between
various regions of Poland, with the lowest
Table 4. Source of Staphylococcus aureus isolates from
hospitalised patients
Sample type
Total
(n = 1003)
MSSA
(n = 826; 82.3%)
MRSA
(n = 177; 17.6%)
Skin and soft tissue 284 240 44 (15.5%)
Surgical site infection 251 196 55 (21.9%)
Deep abscess 87 77 10 (11.5%)
Blood 102 82 20 (19.6%)
Joint and bone infection 74 59 15 (20.2%)
Otitis media 22 22 –
Conjunctivitis 17 17 –
Urinary tract infection 19 17 2 (10.5%)
Others 122 97 25 (20.5%)
Unknown 25 19 6 (24%)
MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus.
Fig. 3. MRSA prevalence (%) by regions of Poland.
n = number of all hospital isolates from each region.
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percentage of MRSA being found in the least
industrialised, rural eastern area, where mainly
primary-care facilities exist. Although the num-
ber of isolates ⁄ centre was low, the number of
resistant isolates in each region was calculated
from data from >30 laboratories. Pronounced
geographical variations have also been reported
previously in the prevalence of MRSA in differ-
ent countries, and in different locations within a
single country [2,23,24]. This emphasises the
necessity of monitoring the local incidence of
MRSA in order to optimise empirical therapy and
infection control practices. With an overall fre-
quency of 17.6%, Poland is in the middle of the
range of MRSA incidence among European
countries. For many years, the Scandinavian
countries and The Netherlands have had the
lowest incidence (1%), and Greece, Italy and
France have had some of the highest incidences
(> 40%) [25,26]. A signiﬁcant increase in the
incidence of MRSA has also been observed
recently among isolates of S. aureus recovered in
the UK [25,27]. Polish MRSA isolates are multi-
resistant, being fully susceptible only to glyco-
peptides and linezolid (personal unpublished
data) [24,28,29]. No isolates with lowered sus-
ceptibility to glycopeptide antibiotics were iden-
tiﬁed in the present study, although the ﬁrst such
isolates have been detected in Poland [30]. Most
MRSA isolates from Poland are susceptible to
minocycline [31], which has never been regis-
tered for use in Poland. The highest proportion of
MRSA isolates was noted in intensive care units,
underlining the necessity for strict infection
control measures in the care of critically ill
patients. In contrast, MSSA isolates from nosoco-
mial and community-acquired infections were
mostly susceptible to all the antimicrobial agents
tested except tetracycline, which may be the
result of the high consumption of this drug in
Poland for many years. However, it should be
stressed that the presence of the inducible resist-
ance phenotype should be investigated when
testing susceptibility to macrolides and lincosa-
mides, since MIC data underestimate the per-
centage of non-susceptible isolates.
In contrast to other countries, the present study
identiﬁed a low susceptibility of MRSA isolates to
rifampicin in Poland, although similar results
have been obtained in some regions of Australia
[32–34]. Resistance may arise in tuberculosis
patients treated with rifampicin [35], and rifampi-
cin is used extensively in Poland as part of
combination therapy for tuberculosis, which has
a relatively high incidence in the Polish popula-
tion (26.5 ⁄ 100 000; http://www.pzh.gov.pl).
Overall, the present study emphasised that
changing patterns of resistance among clinically
important bacterial pathogens require careful
monitoring and a consistently high quality of
hospital laboratory testing.
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